The Quantellect read.As of Nov 19, 2026, 5 active firms cover Tectonic Therapeutic, Inc: 4 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $26.00 to $93.00 (about 3.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $68.75 sits 226% above the current $21.06. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.30 next quarter toward $-4.76 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy120%
Buy360%
Neutral120%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$68.75
+226.4% upside
Average target across 4 active firms as of Nov 19, 2026 vs $21.06 current
Highest Target$93.00
Average Target$68.75
Lowest Target$26.00
Detailed analyst forecasts for TECX
Showing 1–4 of 4 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 4 of 5 active firms rate TECX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TECX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.30
Range $-1.55 – $-0.86 · 5 analysts · -3% YoY
Next period, 5 analysts expect Tectonic Therapeutic, Inc. to earn $-1.30 a share (range $-1.55 – $-0.86), versus $-1.34 a year earlier. Full-year consensus is $-5.77, growing to $-4.76 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Tectonic Therapeutic, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TECX.
#1
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$76.00+260.9% to target
Overall win rate
30%
+ Follow
#2
JC
James Condulis
Stifel
Buy
$75.00+256.1% to target
Coverage
—
+ Follow
#3
Benjamin Burnett
Wells Fargo
Buy
$93.00+341.6% to target
Coverage
—
+ Follow
#4
DB
Danielle Brill
Truist Securities
Buy
$60.00+184.9% to target
Coverage
—
+ Follow
#5
MF
Michael Freeman
Raymond James
Buy
$81.00+284.6% to target
Coverage
—
+ Follow
TECX stock forecast FAQ
What is TECX's average 12-month price target?+
The 4 active firms with a live target average $68.75 for Tectonic Therapeutic, Inc. over the next 12 months, ranging from a $93.00 high to a $26.00 low, as of Nov 19, 2026.
Is TECX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TECX?+
The Street-high target is $93.00 (Wells Fargo), and the Street-low is $26.00 (UBS). The average of all 4 active-firm targets is $68.75.
How many active Wall Street firms cover TECX?+
5 active firms have a recognized rating on Tectonic Therapeutic, Inc. as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TECX?+
Among analysts who currently cover TECX, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #339). Their current call is Buy with a $76.00 target.
What is Tectonic Therapeutic, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-1.30 per share (range $-1.55 – $-0.86) across 5 analysts. Full-year EPS is projected at $-5.77, rising to $-4.76 the following year.
How much revenue is Tectonic Therapeutic, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading TECX lately?+
As of Nov 19, 2026, 4 of 5 active firms rate TECX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TECX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.